- Home
- ALAR vs AVIR Comparison
ALAR vs AVIR Comparison
Compare ALAR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- AVIR
- Stock Information
- Founded
- ALAR 2013
- AVIR 2012
- Country
- ALAR Israel
- AVIR United States
- Employees
- ALAR N/A
- AVIR N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- ALAR Technology
- AVIR Health Care
- Exchange
- ALAR Nasdaq
- AVIR Nasdaq
- Market Cap
- ALAR 70.7M
- AVIR 290.4M
- IPO Year
- ALAR 2018
- AVIR 2020
- Fundamental
- Price
- ALAR $18.51
- AVIR $3.59
- Analyst Decision
- ALAR Strong Buy
- AVIR Hold
- Analyst Count
- ALAR 2
- AVIR 1
- Target Price
- ALAR $25.50
- AVIR $6.88
- AVG Volume (30 Days)
- ALAR 403.8K
- AVIR 153.0K
- Earning Date
- ALAR 11-26-2024
- AVIR 11-06-2024
- Dividend Yield
- ALAR N/A
- AVIR N/A
- EPS Growth
- ALAR N/A
- AVIR N/A
- EPS
- ALAR 0.07
- AVIR N/A
- Revenue
- ALAR $31,117,000.00
- AVIR N/A
- Revenue This Year
- ALAR $22.15
- AVIR N/A
- Revenue Next Year
- ALAR $11.59
- AVIR N/A
- P/E Ratio
- ALAR $29.65
- AVIR N/A
- Revenue Growth
- ALAR 52.26
- AVIR N/A
- 52 Week Low
- ALAR $2.92
- AVIR $2.77
- 52 Week High
- ALAR $46.69
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- ALAR 70.83
- AVIR 50.72
- Support Level
- ALAR $8.97
- AVIR $3.31
- Resistance Level
- ALAR $21.50
- AVIR $3.49
- Average True Range (ATR)
- ALAR 1.53
- AVIR 0.12
- MACD
- ALAR 1.28
- AVIR 0.04
- Stochastic Oscillator
- ALAR 76.14
- AVIR 52.21
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).